Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/210004
Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
A set of twenty-five thioxanthene-9-one and xanthene-9-one derivatives, that were previously shown to inhibit cholinesterases (ChEs) and amyloid β (Aβ40) aggregation, were evaluated for the inhibition of tau protein aggregation. All compounds exhibited a good activity, and eight of them (5–8, 10, 14, 15 and 20) shared comparable low micromolar inhibitory potency versus Aβ40 aggregation and human acetylcholinesterase (AChE), while inhibiting human butyrylcholinesterase (BChE) even at submicromolar concentration. Compound 20 showed outstanding biological data, inhibiting tau protein and Aβ40 aggregation with IC50 = 1.8 and 1.3 μM, respectively. Moreover, at 0.1–10 μM it also exhibited neuroprotective activity against tau toxicity induced by okadoic acid in human neuroblastoma SH-SY5Y cells, that was comparable to that of estradiol and PD38. In preliminary toxicity studies, these interesting results for compound 20 are somewhat conflicting with a narrow safety window. However, compound 10, although endowed with a little lower potency for tau and Aβ aggregation inhibition additionally demonstrated good inhibition of ChEs and rather low cytotoxicity. Compound 4 is also worth of note for its high potency as hBChE inhibitor (IC50 = 7 nM) and for the three order of magnitude selectivity versus hAChE. Molecular modelling studies were performed to explain the different behavior of compounds 4 and 20 towards hBChE. The observed balance of the inhibitory potencies versus the relevant targets indicates the thioxanthene-9-one derivatives as potential MTDLs for AD therapy, provided that the safety window will be improved by further structural variations, currently under investigation.
Matèries
Matèries (anglès)
Citació
Citació
TONELLI, Michele, CATTO, Marco, SABATÉ LAGUNAS, Raimon, FRANCESCONI, Valeria, LAURINI, Erik, PRICL, Sabrina, PISANI, Leonardo, MINIERO, Daniela valeria, LIUZZI, Grazia maria, GATTA, Elena, RELINI, Annalisa, GAVÍN MARÍN, Rosalina, RÍO FERNÁNDEZ, José antonio del, SPARATORE, Fabio, CAROTTI, Angelo. Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease. _European Journal of Medicinal Chemistry_. 2023. Vol. 250, núm. 1-12. [consulta: 21 de gener de 2026]. ISSN: 0223-5234. [Disponible a: https://hdl.handle.net/2445/210004]